Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
34.92 CHF | -.--% |
|
-19.92% | -6.81% |
Jun. 26 | Demant Flags Delay in Completion of Communications Business' Strategic Review | MT |
May. 29 | UK’s Competition Regulator Closes Cochlear-Demant Deal | MT |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's enterprise value to sales, at 3.38 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.81% | 9.43B | - | ||
+0.04% | 18.12B | A | ||
+9.31% | 14.37B | B | ||
+7.83% | 1.73B | B+ | ||
-30.39% | 1.73B | - | ||
+6.10% | 1.26B | D- | ||
-5.81% | 490M | - | ||
0.00% | 352M | - | - | |
+95.67% | 226M | - | ||
+22.67% | 105M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DEMANT Stock
- WDH1 Stock
- Ratings Demant A/S